BindingDB logo
myBDB logout

null

SMILES: COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCOC(=O)C(N)CC(C)C)c2ccccc12

InChI Key: InChIKey=ZKLYZABPCRFWBD-UHFFFAOYSA-N

Find this compound or compounds like it in BindingDB or PDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 147463   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Vascular endothelial growth factor receptor 2


(Homo sapiens (Human))
BDBM147463
PNG
(US8957103, D)
Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCOC(=O)C(N)CC(C)C)c2ccccc12 |t:13|
Show InChI InChI=1S/C29H33N3O7/c1-16(2)12-20(30)29(35)39-11-10-32-15-19(18-8-6-7-9-21(18)32)25-24(27(33)31-28(25)34)17-13-22(36-3)26(38-5)23(14-17)37-4/h6-9,13-16,20H,10-12,30H2,1-5H3,(H,31,33,34)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
KEGG
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 251n/an/an/an/an/an/a



Johannes Gutenberg—Universitat Mainz

US Patent


Assay Description
The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...


US Patent US8957103 (2015)


BindingDB Entry DOI: 10.7270/Q2SJ1J99
More data for this
Ligand-Target Pair
Glycogen synthase kinase-3 beta


(Homo sapiens (Human))
BDBM147463
PNG
(US8957103, D)
Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCOC(=O)C(N)CC(C)C)c2ccccc12 |t:13|
Show InChI InChI=1S/C29H33N3O7/c1-16(2)12-20(30)29(35)39-11-10-32-15-19(18-8-6-7-9-21(18)32)25-24(27(33)31-28(25)34)17-13-22(36-3)26(38-5)23(14-17)37-4/h6-9,13-16,20H,10-12,30H2,1-5H3,(H,31,33,34)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
KEGG
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 12n/an/an/an/an/an/a



Johannes Gutenberg—Universitat Mainz

US Patent


Assay Description
The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...


US Patent US8957103 (2015)


BindingDB Entry DOI: 10.7270/Q2SJ1J99
More data for this
Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))
BDBM147463
PNG
(US8957103, D)
Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCOC(=O)C(N)CC(C)C)c2ccccc12 |t:13|
Show InChI InChI=1S/C29H33N3O7/c1-16(2)12-20(30)29(35)39-11-10-32-15-19(18-8-6-7-9-21(18)32)25-24(27(33)31-28(25)34)17-13-22(36-3)26(38-5)23(14-17)37-4/h6-9,13-16,20H,10-12,30H2,1-5H3,(H,31,33,34)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
KEGG
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 239n/an/an/an/an/an/a



Johannes Gutenberg—Universitat Mainz

US Patent


Assay Description
The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...


US Patent US8957103 (2015)


BindingDB Entry DOI: 10.7270/Q2SJ1J99
More data for this
Ligand-Target Pair